(Invited) Biodistribution, Pharmacokinetics and Toxicology of Graphene Quantum Dots – an in vivo Study

Authors:

Abstract
Graphene quantum dots (GQDs) serve as remarkable agents for drug and gene therapeutic delivery targeted treatment of complex diseases including cancer, sensing of biomolecules, cancer-generated genes and environmental conditions including the temperature and pH. GQDs design to emit fluorescence in the near-infrared (NIR) due to its high penetration depth are now utilized in biological imaging within subcellular and intracellular environments as well as in biological tissues and live animal models. Given their promising potential in image-guided delivery, the outlets of NIR-emissive GQDs in live targets need to be explored to further focus and enhance their applications in vivo. In the present work we explore GQD in vivo toxicity (describing maximum amounts that could be used for delivery and imaging), biodistribution (showing the tissues that can be targeted by the GQDs and the regions within particular animal tissues that acquire maximum GQD accumulation) and pharmacokinetics (showing GQD circulation times in blood that could help identify relevant clinical targets). In this study GQD content is analyzed vi a NIR fluorescence imaging allowing for semi-quantitative assessment through the layers of biological tissue. When injected intravenously (IV) or intraperitonially (IP) into live BALB/c mice GQDs distribute into multiple murine organs with maximum fluorescence intensity in liver, kidneys spleen, heart, spleen, thymus, brain and joints with most of the organs experiencing maximum accumulations at 6 – 24 h time points. During first pass metabolism we expect GRDs to partially clear through liver and kidneys. Kidneys expectedly experience faster (~1 h) clearance of the GQDs than liver (6 – 12 h) with the prolonged residence time noted for spleen (12 – 24 h). While the bulk fluorescence signal provides semi-quantitative accumulation information, the location of the GQDs within the tissue in the cells is further studied in animal organ slice microscopy that explores the possibility of GQDs entering such complex targets as brain. While accumulation in the majority of the aforementioned organ targets is expected from metabolic pathways of the GQDs, their high and prominent in mouse joints with over 48 h retention times is unforeseen and can serve toward advancement of joint therapy delivery and joint imaging applications. While being amphiphilic but only nanometer-sized particles, GQDs experience appreciable blood circulation times of 3.8 h allowing for a variety of therapeutic delivery approaches including even non-targeted cancer therapeutics. Their early-stage clearance is attributed to the renal pathway, while at later time points it is expected to be dominated by the reticuloendothelial system. Toxicologically GQDs appear to be superior to a plethora of their nanomaterial counterparts with concentration up to 16.5 mg/mL showing no toxic response in mice in terms of weight and behavior for the period of 3 weeks post administration. These concentrations are surpass the ones used for imaging 10-fold. Conformational tissue changes are further analyzed using H&E-stained organ slice microscopy. This work demonstrates that GQDs have a promising potential to serve as a viable platform for therapeutic delivery and imaging in multiple organs at ultra-high non-toxic concentrations with their circulation times allowing for anticancer therapeutic delivery applications.